author-photo

Heather P. Becker

University of Chicago

4

Papers

567

Citations

Citation Trend

Filter By

Papers (4) Sort By

Journal Conference Others

Comparison of Doxorubicin and Cyclophosphamide Versus Single-Agent Paclitaxel As Adjuvant Therapy for Breast Cancer in Women With 0 to 3 Positive Axillary Nodes: CALGB 40101 (Alliance)

2014 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (61)
Six Cycles of Doxorubicin and Cyclophosphamide or Paclitaxel Are Not Superior to Four Cycles As Adjuvant Chemotherapy for Breast Cancer in Women With Zero to Three Positive Axillary Nodes: Cancer and Leukemia Group B 40101

2012 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (71)
Abstract S6-3: Four vs 6 Cycles of Doxorubicin and Cyclophosphamide (AC) or Paclitaxel (T) as Adjuvant Therapy for Breast Cancer in Women with 0-3 Positive Axillary Nodes: CALGB 40101 — A 2x2 Factorial Phase III Trial: First Results Comparing 4 vs 6 Cycles of Therapy

2010 Cancer Research
Show All
- Source
- Cite
- Save
Citations (4)
Adjuvant chemotherapy in older women with early-stage breast cancer.

2009 The New England Journal of Medicine
Show All
- Source
- Cite
- Save
Citations (431)